NASDAQ · SLN
Silence Therapeutics plc
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
Loading market information…
NASDAQ · LYEL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lyell Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lyell Immunopharma, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$2.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lyell Immunopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$3.600.0% vs estimate | $7.00K0.0% vs estimate |
|---|
| Q4 2024 | Mar 11, 2025 | -$14.40-323.53% vs estimate | $11.00K |
|---|
| Q3 2024 | Nov 7, 2024 | -$3.40-1,600.0% vs estimate | $34.00K |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $45.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$5.85-$0.04 (-0.68%)
Kyverna Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
$2.67+$0.13 (+5.12%)
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
$1.59+$0.07 (+4.28%)
Cabaletta Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.53% below the high.
$12.74-$0.01 (-0.08%)
Amarin Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 26.43% below the high.
$2.37$0.00 (0.0%)
AC Immune S.A.’s quoted price sits in the lower half of its reported 52-week range, 39.23% below the high.
